Latest Information Update: 15 Mar 1999
At a glance
- Originator GlaxoSmithKline
- Class Obesity therapies
- Mechanism of Action Cholecystokinin A receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 15 Mar 1999 Discontinued-Clinical for Obesity in United Kingdom (Unknown route)
- 09 Jan 1998 Investigation in Obesity in United Kingdom (Unknown route)
- 14 Jul 1997 New profile